Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$4.76 - $6.59 $357,742 - $495,278
75,156 Added 20.21%
446,951 $2.13 Million
Q1 2023

May 10, 2023

BUY
$4.24 - $11.12 $1.58 Million - $4.13 Million
371,795 New
371,795 $2.12 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Jupiter Asset Management LTD Portfolio

Follow Jupiter Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jupiter Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Jupiter Asset Management LTD with notifications on news.